Arkolith/Insider Trading/RGNX/Form 4

Mills Kenneth T.

DirectorREGENXBIO Inc. (RGNX) · full profile →Form 4 · filed May 14, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$163K
Net Open-Market Flow
-$163K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 12, 2025Option exercise(M)21K$3.76$77K496K
May 12, 2025Sell(S)21K$7.91$163K475K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 12, 2025Option exercise(M)21K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-25-003822) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML